RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug
RAPT Therapeutics shares soared 64% to $57.54 after GSK announced a $58-per-share cash acquisition, valuing the biotech at $2.2 billion. The deal centers on ozureprubart, an experimental anti-IgE drug for food allergies. GSK plans to launch a tender offer within 10 business days, pending antitrust review. RAPT’s stock hovered just below the offer price as investors watched for regulatory developments.